Prevalence of High Bleeding Risk Patients According to the Academic Research Consortium for High Bleeding Risk (ARC-HBR) Criteria and the Incidence of Bleeding Outcomes in South-east Asian Patients Who Received Percutaneous Coronary Intervention: A Single-center Retrospective Study
Pannipa Suwannasom1, Tasalak Thonghong2, Srun Kuanprasert2
Maharaj Nakorn Chiang Mai Hospital, Thailand1, Chiang Mai University, Thailand2
The prevalence and incidence of bleeding outcomes according to the Academic Research Consortium for high bleeding risk (ARC-HBR) criteria in the south-east Asian population remain unclear in real-world practices. We sought to validate the ARC-HBR criteria for south-east Asian patients who received percutaneous coronary intervention(PCI).
This retrospective study included all Thai patients who received PCI between May 2018 to July 2019 at a tertiary-care center. The patients were retrospectively adjudicated into high bleeding risk (HBR) group if their characteristics met at least 1 major or2 minor ARC-HBR criteria. The primary outcome was the bleeding events according to bleeding academic research consortium (BARC) type 2,3, and 5 occurred in hospital admission until 1-year follow-up. The secondary endpoint was all-cause mortality.
Among 599 patients who received PCI, 80 patients were excluded from the analysis due to incomplete baseline data for HBR adjudication. There were 198 patients (38.2%) classified in the HBR group and 321 patients (61.8%) did not meet HBR criteria. The mean number of HBR criteria was 1.00 ± 0.98 The most common major and minor HBRcriteria was hemoglobin < 11 g/dL(50.5%) and age > 75 years (46.5%), respectively. The incidence of bleeding was frequently observed in the HBR group (6.6%) than the non-HBR group (1.9%), p=0.008. Patients in the HBR group had higher mortality rates than the non-HBR group (18.2% vs. 4.0%, p < 0.001).
In a retrospective study, 38.2% of south-east Asian patients who received PCI were high bleeding risk patients. The ARC-HBR criteria identified patients at high bleeding and all-cause mortality at 1-year follow-up.